RESUMEN
Objective: To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) co-infected patients. Methods: All NS3 and NS5B HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved from NCBI GenBank database. And sequences were aligned and analyzed using software MEGA 5.0. Results: In total, the overall prevalence of DAAs RAVs in NS3 region was high (26.06% and 38. 18%, respectively), no matter in genotype 1a or genotype 1b. In genotype 1a, the high prevalence of RAVs mainly presented in the position Q80 (8.45%). In genotype 1b, S122 RAV was most observed (36.36%). It is worth noting that, RAVs in NS5B region were rare observed (0.77%) in this study, especially as no RAV was detected in any sequence of genotype 1a patients. Conclusion: The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients, suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.
RESUMEN
Objective·To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infected patients.Methods·All NS3 and NSSB HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved from NCBI GenBank database.And sequences were aligned and analyzed using software MEGA 5.0.Results·In total,the overall prevalence of DAAs RAVs in NS3 region was high (26.06％ and 38.18％,respectively),no matter in genotype 1a or genotype 1b.In genotype 1a,the high prevalence of RAVs mainly presented in the position Q80 (8.45％).In genotype lb,S122 RAV was most observed (36.36％).It is worth noting that,RAVs in NS5B region were rare observed (0.77％) in this study,especially as no RAV was detected in any sequence of genotype 1a patients.Conclusion·The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients,suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.
RESUMEN
Objective To analyze hepatitis C virus genotype(HCV GT)1b NS5A resistance-associated variants(RAV)and its related factors,and to provide references for direct-acting antivirals (DAA)agent selection and application.Methods From January 2017 to July 2017,53 hepatitis C patients were selected from the Department of Infectious Diseases of Henan Province People's Hospital. The mutations of L31M and Y93H in NS5A RAV were analyzed in 43 HCV GT1b patients,and their correlations with hepatitis C virus,liver function,platelet and liver fibrosis diagnostic model[APRI, gamma-glutamyl transpeptidase to platelet ratio(GPR),FIb-4]were analyzed.The quantitative data were compared by two independent samples t test,and the qualitative data were compared by chi square test. Results Fifty-three subjects were enrolled,including 43 GT1b(9 males and 34 females)and 10 GT2a(2 males and 8 females).No other genotype was detected.The incidence of NS5A RAV in 43 HCV GT1b patients was 13.9%(6/43),of which L31M and Y93H were 1/43(2.3%)and 5/43(11.6%)with no significant difference(χ2= 1.500,P= 0.219).There were no significant differences in HCV RNA, ALT,AST,albumin,platelets and age between patients with or without mutation(all P> 0.05). Conclusions The incidence of NS5A RAV in HCV GT1b patients is high,but not affected by virus, biochemical factors and liver fibrosis.The detection of NS5A RAV before HCV treatment is helpful for rational selection of DAA,which could reduce the drug resistance.